---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028750"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:01:44.488475+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharma Q2 net loss $31.2M; XEN1101 Phase 3 on track for H2 2022

## Summary
- Net loss of $31.2M for Q2 2022, up from $22.1M in Q2 2021.
- Cash and securities $788.2M as of June 30, 2022, extended runway into 2026.
- Revenue fell to $0.5M from $2.2M, mainly due to wind-down of Neurocrine collaboration.
- XEN1101 Phase 3 X-TOLE2 expected to start in H2 2022 after positive FDA End-of-Phase 2 meeting.
- XEN496 EPIK study for KCNQ2-DEE anticipated to complete in 2023.

## SEC filing metadata
- accession: 0001564590-22-028750
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000156459022028750/0001564590-22-028750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000156459022028750/xene-8k_20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028750
- JSON: https://secwatch.observer/filing/0001564590-22-028750.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.